A scan that makes prostate cancer cells “glow” could halve the number of men needing invasive biopsies, research suggests.

Australian scientists say it could also help reduce the risk of overdiagnosis by determining which cancers are low-risk and ...

Urologists, radiologists and pathologists from Europe and the US agreed an “expert consensus statement” on prostate cancer ...

MRI of the prostate, combined with a blood test, can help determine if a prostate lesion is clinically significant cancer, new research suggests. A new meta-analysis by investigators from Brigham and ...

An imaging test could safely halve the number of people who need a biopsy for suspected prostate cancer following ...

Scans that make prostate cancer cells glow can eliminate the need for invasive biopsies and cut false positive—and they're ...

High-resolution microultrasonography-guided biopsy was non-inferior to MRI fusion-guided biopsy for detecting clinically significant prostate cancer (detection rates, 47.1% and 42.6%, respectively), a ...

A large screening trial showed that using prostate-specific antigen density (PSAD) before MRI prevented overdiagnosis and lowered resource use while preserving the detection of clinically significant ...

There is both good news and bad news about prostate cancer screening. First, the bad news: the blood test involved, which measures a compound called prostate-specific antigen (PSA), is too inaccurate.

Prostate cancer is one of the leading causes of cancer-related death in men, and some experts project the number of cases to rise over the coming decades. But in a recent Urologic Oncology article, ...

Prostate cancer kills more than 12,000 men a year in the UK, slightly more than the number of women who die from breast ...